Rare coding variants in schizophrenia-associated genes affect generalised cognition in the UK Biobank

Author list and affiliations:

Eilidh Fenner[1], Peter Holmans[1], Michael C O'Donovan[1], Michael J Owen[1], James T R Walters[1+*], Elliott Rees[1+*]

1. Centre for Neuropsychiatric Genetics and Genomics, Division of Psychological Medicine and Clinical Neurosciences, Cardiff University, Cardiff, UK

[+] these authors contributed equally to this work. *Corresponding authors.

Corresponding authors:

Dr Elliott Rees

Hadyn Ellis Building, Maindy Road, Cardiff, CF24 4HQ

Phone: +44 (0)29 2068 8375

Email: ReesEG@cardiff.ac.uk

Professor James T R Walters

Hadyn Ellis Building, Maindy Road, Cardiff, CF24 4HQ

Phone: +44 29206 88434

Email: WaltersJT@cardiff.ac.uk

Abstract/Summary

Cognitive impairments in schizophrenia are associated with poor outcomes and are largely unimproved by current medications. It remains uncertain to what extent cognitive impairments arise from shared aetiology and biology with schizophrenia, or are a consequence of having the condition. We analysed exome-sequencing data from 76,783 UK Biobank participants without schizophrenia to test for association between generalised cognition (*g*) and rare (minor allele count≤5) variants in schizophrenia-associated genes. Protein-truncating and deleterious missense variants in loss-of-function intolerant genes were associated with lower *g*. Stronger effects on *g* were found for protein-truncating variants in genes implicated in schizophrenia by rare coding variation, and for deleterious missense variants in credible causal genes at schizophrenia common allele loci. These findings indicate that biological processes disrupted in schizophrenia by common and rare variants are associated with *g* in unaffected individuals, suggesting the relationship between impaired cognition and schizophrenia reflects, in part, a shared underlying biology.

Keywords: Schizophrenia, cognition, generalised cognition, rare variants, UK Biobank

Graphical Abstract:



Figure 1 – Graphical abstract. RCVs = rare coding variants. QC = quality control. *g* = generalised cognition.

Introduction

Schizophrenia is a severe and clinically heterogeneous psychiatric disorder with a lifetime prevalence of just under 1%[1,2]. Impaired cognitive function is an important feature of schizophrenia that often precedes the onset of psychosis[3–5] and is a strong predictor of functional outcomes, encompassing social, occupational, educational, and interpersonal functioning, the ability to live independently, and the ability to engage in day-to-day activities[6,7]. Relative to controls, those with schizophrenia demonstrate impairments across multiple cognitive domains, suggesting the disorder is associated with a generalised, rather than a domain specific, cognitive impairment. Indeed, measures of generalised cognition, or *g*, in individuals with schizophrenia are on average around 1.5 standard deviations lower than in controls[8–10]. Furthermore, *g* explains the majority of variance in cognition between people with schizophrenia and healthy controls, and is also a better predictor of functional outcome in schizophrenia than any individual cognitive test[11,12].

56 Schizophrenia is highly heritable and polygenic, with liability conferred by rare and common
57 alleles in many genes, particularly those under selective constraint against mutations
58 predicted to result in a loss of protein function, also known as loss-of-function intolerant
59 (LoFi) genes[13–15]. The largest genome-wide association study (GWAS) of common alleles
60 (minor allele frequency (MAF) > 1%) in schizophrenia to date identified 287 distinct
61 associated loci[16], and among these, fine-mapping prioritised 106 protein-coding genes as
62 credibly causal. The genome-wide burden of rare copy number variants (CNVs) is also
63 increased in schizophrenia cases compared with controls, with a set of 63 CNVs reported to
64 be associated with developmental disorders showing particular enrichment in cases[17,18].
65 Moreover, 13 of these CNVs have been robustly associated with schizophrenia liability[17,18].
66 Finally, sequencing studies have identified 12 genes that are individually enriched in
67 schizophrenia for damaging types of rare coding variants (RCVs)[19,20]. There is also evidence
68 for a convergence between genes implicated in schizophrenia by common and rare
69 alleles[16,19].

70 Genetic liability for schizophrenia is pleiotropic, with shared effects on liability to several
71 other psychiatric and developmental disorders as well as on variation in cognitive function in
72 the general population. For example, the 13 CNVs robustly associated with schizophrenia are
73 all risk factors for developmental disorders[17], and individuals without a psychiatric or
74 developmental disorder who carry one of these CNVs perform worse on a range of cognitive
75 tests compared to those who do not have such CNVs[21,22]. Similarly, damaging RCVs in
76 developmental disorder-associated genes are associated with poorer cognition in individuals
77 without a psychiatric or developmental disorder[23,24]. Finally, a higher burden of
78 schizophrenia common alleles is associated with lower cognitive function in the
79 population[25,26].

80 Less is known about the effects of damaging RCVs in schizophrenia genes and loci on
81 cognition in individuals without a diagnosis of schizophrenia, autism spectrum disorder
82 (ASD) or intellectual disability (ID). Studying these individuals helps isolate the direct
83 effects of rare variant liability for schizophrenia on cognition, independent of the effects of
84 other factors related to the pathophysiology of the disorder, or that emerge as a consequence
85 of schizophrenia or other neurodevelopmental disorders (NDDs) (e.g. antipsychotic
86 medication use, long-term symptoms, or lifestyle factors). This reduces the risk of reverse
87 causation, whereby differences in cognitive ability may be a consequence of the disorder
88 and/or its treatment. It is therefore important to establish whether damaging RCVs in
89 schizophrenia-associated genes impact cognition in those unaffected by this disorder, as this
90 would provide evidence that the association of impaired cognition with schizophrenia is, at
91 least in part, explained by shared biology between schizophrenia and cognitive function.

92 Recent studies using data from the UK Biobank (UKBB) have shown damaging RCVs in
93 LoFi genes are associated with longer reaction-time, lower fluid intelligence scores, and
94 lower levels of educational attainment[23,27]. One study also reported that damaging RCVs in
95 genes mapping to schizophrenia loci identified by GWAS are significantly associated with
96 lower educational attainment, and also nominally significantly associated with longer
97 reaction-time and lower fluid intelligence[23]. However, that study did not determine whether
98 this association was attributable to those loci being associated with schizophrenia, or whether
99 it was confounded by the fact that LoFi and brain-expressed genes are enriched both within
100 these schizophrenia loci[15]. It also did not test the specific genes within those loci that have
101 been reported to be credibly causal. There has also been no study examining the relationship
102 between cognition in individuals without a psychiatric or developmental disorder and RCVs
103 in sets of genes implicated in schizophrenia by rare CNVs or RCVs.

104 In the current study, we analysed exome sequencing data from 396,848 unrelated participants
105 passing quality control (QC) in the UKBB to examine whether damaging RCVs in genes
106 implicated in schizophrenia have effects on cognition in people without a diagnosis of
107 schizophrenia, ASD, or ID (full study design presented in Methods). Whereas previous RCV
108 studies of cognition in the UKBB analysed only individual tests of cognition[23,24], we analysed
109 a measure of generalised cognition (*g*), which we formed from a principal component
110 analysis of four cognitive tests. We focussed our study on *g*, instead of individual cognitive
111 tests, as it is a more robust measure of general cognitive ability, and also because
112 schizophrenia is strongly associated with a generalised rather than a specific cognitive
113 deficit[12,28,29]. Our findings demonstrate that rare protein-truncating variants (PTVs) and
114 damaging missense variants in LoFi genes are associated with lower *g*, which to our
115 knowledge has not been shown before. We also show that rare PTVs in genes implicated in
116 schizophrenia by RCVs have a significantly stronger effect on *g* than that observed for rare
117 PTVs in LoFi genes and brain-expressed genes. Additionally, rare deleterious missense
118 variants in credible causal genes underlying schizophrenia common allele loci were
119 associated with lower *g,* and this effect was significantly stronger than that observed for rare
120 deleterious missense variants in all genes mapping to the schizophrenia common allele loci,
121 and for rare deleterious missense variants in LoFi genes or brain-expressed genes.

122 Overall, these findings indicate that biological processes disrupted in schizophrenia by
123 common and rare variants are linked to generalised cognitive function in unaffected
124 individuals. This suggests the association of impaired cognition with schizophrenia reflects
125 shared underlying biology between schizophrenia and cognitive function.

126 # Results

127 ## Distribution of protein-coding variation

128 19,724,617 high-quality autosomal protein coding variants were observed in 396,848
129 unrelated UKBB participants that passed quality control (QC). We defined rare variants as
130 those with a minor allele count (MAC) ≤ 5 (equating to a MAF < 6.25 x 10^{-6}), a definition
131 similar to that of other UKBB rare variant studies[23,24]. 75.6% of observed variants were rare.
132 Substantial variation was observed in the number of rare variants per participant across
133 genetic ancestries (Supplementary Table 1; see Supplementary Materials 1.1 for detail on
134 ancestry inference), with participants that were genetically similar to the 1000 Genomes[30]
135 European superpopulation (1KGP-EUR-like) carrying fewer rare damaging variants (mean
136 number of rare PTVs carried = 2.02) compared with participants genetically similar to other
137 1KGP superpopulations (mean number of rare PTVs carried ranging from 5.80 to 8.51;
138 Supplementary Table 1). This difference was expected given allele frequencies were defined
139 by the UKBB sample itself, and 95% of the cohort were of 1KGP-EUR-like genetic ancestry.
140 We controlled for differences in the rates of RCVs across populations by analysing
141 participants in each genetically inferred ancestry group separately.

142 ## Estimating generalised cognition in the UKBB

143 Generalised cognition (*g*) was estimated in 76,783 participants that passed QC (see Methods
144 and Supplementary Materials 1.2 for a full description of how *g* was derived). In these
145 participants, *g* explained 38.9% of the variance of the tests included in its formation (numeric
146 memory, reaction time, pairs matching, and trail making test B; see Supplementary Table 2
147 for a description of these tests). As expected, *g* was moderately correlated with each of the
148 individual tests used in its derivation (weakest correlation coefficient = -0.53, Supplementary
149 Table 3), as well as with cognitive tests not used to derive *g* (weakest correlation co-efficient

150 = 0.41, Supplementary Table 3). All correlations of *g* and individual cognitive tests were in
151 the expected direction, where higher *g* correlated with higher score on each test (we note that
152 negative correlation coefficients are expected when lower scores for a given test indicate
153 higher cognitive ability). These results suggest *g* forms a cross-domain measure of
154 generalised cognition. We performed a sensitivity analysis of *g* by modifying some of the
155 individual cognitive tests included in its formation (see Supplementary Materials 1.3 for
156 details) and found alternative estimates of *g* were highly correlated with the original estimate
157 (weakest correlation co-efficient = 0.8, Supplementary Table 4), suggesting *g* is robust to
158 different input measures.

159 Rare coding variants in schizophrenia-associated genes
160 and generalised cognition

161 We investigated the relationship between damaging RCVs in schizophrenia-associated genes
162 and *g* in UKBB participants without a diagnosis of schizophrenia, ASD, or ID (see
163 Supplementary Figure 1 for a summary of analyses). We focussed our analysis on the
164 following classes of rare variant: PTVs (splice acceptor, splice donor, stop-gain and
165 frameshift variants predicted with high-confidence to cause loss of protein function[31,32]);
166 deleterious missense variants (REVEL[33] scores > 0.75); and synonymous variants. We
167 investigated the impact on cognition of these variants in LoFi genes defined by GnomAD pLI
168 scores[34] ≥ 0.9, and in sets of genes implicated in schizophrenia by the largest RCV[19],
169 common allele GWAS[16], and CNV studies[17,18] of the disorder (see Methods and
170 Supplementary Table 5 for a description of the gene sets tested).

171 **Constrained and brain expressed genes**

172 In UKBB participants that were genetically similar to the 1KGP[30] European superpopulation,
173 rare PTVs and deleterious missense variants in LoFi genes were associated with lower *g* (rare
174 PTVs: $\beta = -0.062$, $p = 3.3 \times 10^{-17}$; rare deleterious missense variants: $\beta = -0.040$, $p = 6.3 \times 10^{-}$
175 ^{9}; Figure 2; Supplementary Table 6). Rare synonymous variants in LoFi genes were not
176 associated with *g* (Figure 2; Supplementary Table 6). 17.3% of the sample carried at least one
177 rare PTV in a LoFi gene, and 20.5% carried at least one rare deleterious missense variant in a
178 LoFi gene (Supplementary Table 7). A greater number of rare PTVs and deleterious missense
179 variants carried in LoFi genes was associated with lower *g* (Supplementary Figure 2). Similar
180 effects on *g* were observed for RCVs in LoFi genes in males and females (Supplementary
181 Figure 3). For all other genetic ancestry groups tested, no significant effects on *g* were
182 observed for any class of RCV in LoFi genes (Supplementary Table 8), most likely due to
183 small sample sizes. Therefore, all analyses presented hereafter are based on participants that
184 are genetically similar to the 1KGP[30] European superpopulation.

185



Figure 2 – Association between *g* and different classes of rare coding variants in LoF-intolerant and LoF-tolerant genes. Error bars display 95% confidence intervals. LoF = loss-of-function; PTV = protein-truncating variant; *g* = generalised cognition.

The associations of *g* with rare PTVs and rare deleterious missense variants in LoFi genes remained significant when both classes of RCVs were modelled together and after including schizophrenia-enriched CNVs and schizophrenia polygenic risk scores (PRS) in the model (Supplementary Table 9). This suggests that the effect on cognition of each of these classes of genetic variation are largely independent from one another.

Rare PTVs and rare deleterious missense variants in brain expressed genes (as defined in Supplementary Table 5) were associated with lower *g* (PTVs: $\beta = -0.018$, $p = 3.3 \times 10^{-8}$; deleterious missense variants: $\beta = -0.020$, $p = 1.1 \times 10^{-6}$; Supplementary Table 6). Rare PTVs

198 in LoFi genes that were brain expressed had significantly stronger effects on *g* than LoFi
199 genes that were not (z-test p = 0.0099). There was no significant difference in the effects on *g*
200 between rare deleterious missense variants in brain expressed and non-brain expressed LoFi
201 genes (z-test p = 0.47).

202 Rare PTVs and synonymous variants in LoF-tolerant genes were not associated with *g*
203 (Figure 2; Supplementary Table 6). Rare deleterious missense variants in LoF-tolerant genes
204 were associated with lower *g* ($\beta = -0.011$, p = 0.0008; Figure 2; Supplementary Table 6),
205 although the effect size for these variants was significantly weaker than that observed for
206 deleterious missense variants in LoFi genes (z-test p value = 9.8×10^{-5}).

207 To assess whether RCVs in LoFi genes have effects on generalised cognitive ability beyond
208 those captured by individual cognitive tests, we included individual cognitive test scores as
209 covariates in the analysis of *g* with RCV burden in LoFi genes. Controlling for individual
210 cognitive tests that were not included in the formation of *g* (trail-making test A, fluid
211 intelligence, and symbol digit substitution), as well as those that were (numeric memory,
212 reaction time, pairs matching, and trail making test B; see Supplementary Table 2 for a
213 description of all tests), only partly attenuated the significant association between rare PTVs
214 and deleterious missense variants in LoFi genes and *g* (Supplementary Table 10). These
215 findings suggest that damaging RCVs in LoFi genes have broad effects on cognition that
216 extend beyond those captured by any individual cognitive test.

217 **Genes associated with rare coding variants in schizophrenia**

218 We defined genes associated with RCVs in schizophrenia as those implicated in the disorder
219 at a false discovery rate (FDR) < 5% in the Schizophrenia Exome Sequencing Meta-Analysis
220 Consortium (SCHEMA) study[19] (n autosomal genes = 29), hereafter referred to as SCHEMA

221 FDR < 5% genes. Rare PTVs in this set were associated with lower *g* (β = -0.24, p = 0.0004)
222 but rare deleterious missense were not (Figure 3, Supplementary Table 11). PTVs in
223 SCHEMA FDR < 5% genes were associated with *g* with a similar beta (β = -0.24) to that of
224 schizophrenia-enriched CNVs (β = -0.28, Supplementary Table 9). The effect on *g* for rare
225 PTVs in SCHEMA FDR < 5% genes was significantly greater than that observed for rare
226 PTVs in all LoFi genes and brain expressed genes (respective z-test p-values = 0.0038 and
227 0.00045).
228



229

230 **Figure 3 -** Association between *g* and different classes of rare variants in SCHEMA FDR < 5% genes from [19].
231 Error bars display 95% confidence intervals. FDR = false discovery rate; PTV = protein-truncating variant; g =
232 generalised cognition.

233 **Schizophrenia common allele loci**

234 The largest schizophrenia GWAS of common variation to date[16] identified 282 associated
235 autosomal loci and prioritised credible causal protein-coding genes for some of these loci.
236 We analysed RCVs in the following schizophrenia common allele loci gene sets: 1) a broad
237 set including all genes overlapping the common variant loci (n = 1,715); 2) genes closest to
238 the index SNP for each locus (n=186); 3) and genes prioritised as credible causal in that
239 paper[16] (n = 101).

240 Neither rare PTVs nor rare deleterious missense variants in genes mapping to broad
241 schizophrenia common variant loci were associated with *g* (Figure 4, Supplementary Table
242 12). At genes nearest the locus index SNP, rare deleterious missense variants ($\beta = -0.073$, $p =$
243 0.0045) but not rare PTVs were associated with *g* (Supplementary Table 12). The same was
244 true for the credible causal genes (rare deleterious missense variants $\beta = -0.12$, $p = 0.0005$;
245 Figure 4; Supplementary Table 12). The effect on *g* of rare deleterious missense variants in
246 credible causal genes was significantly greater than in non-prioritised genes at GWAS loci (z-
247 test $p = 0.0008$). It was also greater than the effect of rare deleterious missense variants in
248 LoFi genes in general (z-test $p = 0.010$), which is important to demonstrate since
249 schizophrenia common alleles are enriched for LoFi genes[15].



Figure 4 - Association between *g* and different classes of rare variants in various schizophrenia (SZ) common allele loci/ GWAS sets, from [16]. Error bars display 95% confidence intervals. PTV = protein-truncating variant; g = generalised cognition.

Within the credible causal set, rare deleterious missense variants in the 61 fine-map prioritised genes (β = -0.12, p = 0.0029) and in the 44 SMR prioritised genes (4 of which were also prioritised by fine-mapping, β = -0.12, p = 0.046) had similar effect sizes (Supplementary Figure 4; Supplementary Table 12). Prioritisation as a credible causal candidate by SMR[16] required a gene to have an brain eQTL and therefore brain expression could act as a confounder. The effects on *g* for rare deleterious missense variants in credible causal genes, and also in the subset of SMR prioritised genes, were significantly stronger than in all brain-expressed genes that were not part of these respective sets (credible causal

262 genes vs. brain-expressed genes: z-test p = 0.0018; SMR prioritised genes vs. brain-expressed
263 genes: z-test p = 0.048). Thus, the associations we observe here do not simply reflect a
264 background association between *g* and rare deleterious missense variants in brain-expressed
265 genes.

266 **Schizophrenia CNV loci**

267 RCVs in genes mapping to the following sets of CNVs implicated in schizophrenia were
268 tested for association with *g*: 1) schizophrenia-enriched CNVs (n genes = 886), which
269 includes 63 developmental disorder-associated CNVs that are collectively enriched in
270 schizophrenia[17]; 2) schizophrenia-associated CNVs (n genes = 178), which includes 13
271 CNVs with strong evidence for association with schizophrenia. See Methods and
272 Supplementary Table 5 for further details on these CNV gene sets.

273 No class of RCV in the 886 genes mapping to schizophrenia-enriched CNVs was associated
274 with *g* (Figure 5; Supplementary Table 13). Rare PTVs in LoFi genes within the
275 schizophrenia-enriched CNV loci (n = 144) were associated with lower *g* (β = -0.086, p =
276 0.0099, Figure 5, Supplementary Table 13) but the effect size did not significantly differ from
277 that in LoFi genes outside CNV loci (z-test p = 0.23). No class of RCV in LoF-tolerant genes
278 within the schizophrenia-enriched CNV loci was associated with *g* (Figure 5, Supplementary
279 Table 13).



Figure 5 – Association of *g* with different classes of rare variants in genes within schizophrenia-enriched CNV loci. LoFi and LoF-tolerant genes in schizophrenia-enriched CNV loci were also tested separately. Error bars display 95% confidence intervals. LoFi = LoF-intolerant; PTV = protein-truncating variant; *g* = generalised cognition.

No associations with *g* were observed for any class of RCV within the 178 genes mapping to the schizophrenia-associated CNV set or in the subsets of those genes that were LoFi or LoF-tolerant (Supplementary Table 13).

Single gene burden tests

Single-gene association tests were performed for three classes of RCVs (PTVs, deleterious missense variants, and a combined (PTV + deleterious missense) variant class) in 1,003 unique genes taken from the SCHEMA FDR < 5% gene set, the credible causal schizophrenia

292 GWAS gene set, and genes within schizophrenia-enriched CNV loci (number of single gene
293 tests = 3,009). We did not test genes with fewer than five qualifying variants due to a lack of
294 power. No gene showed significant evidence for association after Bonferroni correction
295 (corrected p value 0.05/3,009 = 1.66 x 10^{-5}; Supplementary Table 14).

296 Discussion

297 In the UKBB, we show that damaging RCVs in genes and loci implicated in schizophrenia by
298 common variant and RCV studies are associated with lower *g* in participants without a
299 diagnosis of schizophrenia, ASD or ID. To our knowledge, this is the first study to
300 investigate the relationship between RCVs in schizophrenia genes and *g*. We focussed on *g*,
301 as opposed to individual cognitive tests, for two main reasons. First, a large body of evidence
302 suggests schizophrenia is associated with global cognitive impairment[12,28,29], and compared to
303 controls, people with schizophrenia show greater impairment in *g* than for tests of specific
304 cognitive domains[35]. Second, compared to individual cognitive tests, *g* reduces noise by
305 limiting test-specific error and is a robust measure of general cognitive ability[36–38].

306 Genes under selective constraint for PTVs have consistently been shown to be enriched for
307 common alleles, rare CNVs, and RCVs in people with schizophrenia[13–15]. Here, we provide
308 two novel lines of evidence demonstrating that damaging RCVs in these LoFi genes also
309 contribute to variation in *g* in people without a diagnosis of schizophrenia, ASD, or ID. We
310 first show that rare PTVs and deleterious missense variants in LoFi genes are significantly
311 associated with lower *g,* and that these associations remained significant when adjusting for
312 CNVs and common alleles that confer liability for schizophrenia and are known to influence
313 cognition in unaffected individuals. This suggests the impact of RCVs on *g* is at least
314 partially independent of these other genetic factors. We then show that the association of *g*
315 with RCVs in LoFi genes is not explained by any individual cognitive test, including reaction

316 time and fluid intelligence, both of which have recently been associated with damaging types
317 of RCVs in LoFi genes[23,27]. These findings suggest the impact of these variants extends
318 beyond any individual cognitive domain, and that they have a broad, generalised effect on
319 cognitive function. Such a generalised effect of these RCVs suggests they influence brain
320 mechanisms or systems that control processes central to cross-domain cognition.

321 RCVs in LoFi genes are associated with both schizophrenia and cognition, but there are many
322 LoFi genes and whether the same LoFi genes have pleiotropic effects on schizophrenia and
323 cognition in unaffected individuals is unknown. We show for the first time that carriers of
324 rare PTVs in genes associated with RCVs in schizophrenia have significantly lower *g*, and
325 that the effect of rare PTVs in SCHEMA FDR < 5% genes on *g* is significantly greater than
326 that observed for rare PTVs in LoFi genes and in brain expressed genes. This finding is
327 consistent with genic pleiotropy between schizophrenia and general cognitive function in
328 unaffected individuals. We note that carriers of rare PTVs in SCHEMA FDR < 5% genes had
329 a 0.24 standard deviation decrease in *g*, which is similar to the reduction in *g* observed for
330 carriers of schizophrenia-enriched CNVs (0.28 standard deviations).

331 We also provide novel evidence that rare deleterious missense variants in credible causal
332 genes within schizophrenia-associated common variant loci are associated with lower *g*, and
333 that this is not confounded by the fact that this set of genes is enriched for LoFi genes and
334 those that are brain expressed. These findings advance previous work that only examined the
335 effects on cognitive traits of RCVs in broadly defined schizophrenia common allele loci, and
336 did not control for the effects of constraint or brain expression[23]. In addition, our analysis of
337 schizophrenia credible causal genes also provides orthogonal support for the SMR and fine-
338 mapping approaches used to prioritise credible causal genes for schizophrenia in the study by

339 Trubetskoy et al.[16], suggesting data from population studies of RCVs could assist gene
340 prioritisation within GWAS loci.

341 By finding the strongest effects on *g* for RCVs in genes that have individually been
342 implicated in schizophrenia (i.e. the credible causal genes and RCV associated gene sets), our
343 study supports the hypothesis that the biology of schizophrenia overlaps that for general
344 cognitive function in the population. Highlighting these specific gene sets in which
345 deleterious mutations have particularly strong effects on cognition allows us to more
346 definitively highlight a role of these schizophrenia-associated genes in cognitive impairment.
347 Moreover, these sets of genes have plausible biological links to cognition, given they are
348 enriched for genes encoding proteins related to the synapse[16,19], which has important roles in
349 learning and memory[39].

350 CNVs associated with developmental disorders have previously been shown to be
351 collectively enriched in schizophrenia[17] and associated with lower scores on individual
352 cognitive tests in unaffected individuals[21,22]. In the current study, we mirror findings from
353 other cohorts demonstrating lower generalised cognition in carriers of these CNVs[40]. We also
354 found that rare PTVs in LoFi genes overlapping the CNV loci are associated with lower *g*,
355 however, these effects were not significantly different from those observed for rare PTVs in
356 all LoFi genes, contrasting with findings based on other schizophrenia gene sets. We
357 speculate that this reflects the highly polygenic nature of schizophrenia[41], and the multigenic
358 nature of all but one schizophrenia-associated CNV, a consequence of which would be that
359 unless each CNV contains a large number of schizophrenia-causal genes, the proportion of
360 such genes in CNVs is unlikely to be substantially elevated over LoFi genes in general.

361 The favourable psychometric properties of *g* compared to individual cognitive tests[37,38] is a
362 strength of our study, but the associated requirement for multiple cognitive test scores will
363 almost certainly induce a participation bias that would lead to under-representation of
364 mutations that reduce the likelihood of completing all cognitive tests. This is plausible since
365 previous work has shown that UKBB participants with PTVs in genes associated with ASD
366 or in LoFi genes are less likely to have completed cognitive testing[42]. The known UKBB
367 volunteer bias, whereby participants have a higher average socio-economic status and are
368 generally healthier than the UK population[43] is likely to have a similar effect. Both biases
369 would result in underestimation of the effect sizes of variants that impact *g*, but are unlikely
370 to change the general direction of observed effects[44]. Future research focused on
371 understanding the relationship between different classes of RCVs and participation in the
372 voluntary and cognitive components of the UKBB could inform the interpretation of findings
373 from this and wider studies.

374 While our findings show that damaging RCVs in schizophrenia-associated genes are
375 associated with lower *g* in the general population, the effect sizes we observe may differ in
376 clinical populations, as we studied participants without a diagnosis of schizophrenia, ASD, or
377 ID to reduce the likelihood of our findings reflecting reverse causation. Another limitation
378 this study faced, despite the large sample size, was that some analyses were underpowered;
379 for example, we lacked power to implicate individual genes in cognition. We were also
380 underpowered to analyse RCVs in non-1KGP-EUR-like genetic ancestries. It is important for
381 future work to examine the relationship between damaging RCVs in schizophrenia-associated
382 genes and loci and cognitive function in clinical populations and in more diverse and
383 representative samples.

384 In conclusion, we show for the first time that damaging RCVs in LoFi genes contribute to
385 variation in generalised cognitive function in UKBB participants without a diagnosis of
386 schizophrenia, ASD, or ID, with significantly stronger effects on cognition observed for
387 damaging RCVs in genes previously associated with schizophrenia. These findings suggest
388 that biology impacted in schizophrenia by common and rare alleles is associated with
389 cognitive function in the population, and that the genetic overlap between schizophrenia and
390 cognition in unaffected individuals is not explained by general gene properties such as LoF-
391 intolerance or brain expression. They also suggest that the association of impaired cognition
392 in schizophrenia is, at least in part, explained by shared biology between schizophrenia and
393 cognitive function. Our study demonstrates the utility of exploiting large sequencing datasets
394 of unaffected individuals, such as the UKBB, to identify genes with shared effects on
395 cognition and schizophrenia and provides a route towards determining the biological
396 processes underlying cognitive impairment in the disorder.

397

398 # Methods

399 ## Key Resources Table

REAGENT or RESOURCE	SOURCE	IDENTIFIER
Deposited data		
UK Biobank phenotype, whole exome sequencing, and genotype data	UK Biobank	https://www.ukbiobank.ac.uk/enable-your-research
Software and algorithms		
Hail (v0.2.60) running on a JupyterLab instance on the UKBB research analysis platform (RAP)	Hail Team[45]	https://github.com/hail-is/hail
R (v4.4.0) in RStudio (v2.2.1) running on a Posit Workbench on the UKBB RAP	R core team and Posit	https://cran.r-project.org/ and https://posit.co/
PLINK (v1.9 and v2.0)	Chang *et al.*[46]	https://www.cog-genomics.org/plink/1.9/ and https://www.cog-genomics.org/plink/2.0/
PRSice-2	Wan Choi *et al.*[48]	https://choishingwan.github.io/PRSice/
Ensembl's VEP running in Hail using LoFTEE plugin	VEP: McLaren *et al.*[49] LoFTEE: Karczewski *et al.* [31,32]	https://hail.is/docs/0.2/methods/genetics.html#hail.methods.vep and https://github.com/konradjk/loftee
r/ggplot2 (v3.5.1)	Wickham[50]	https://ggplot2.tidyverse.org/
r/ukbtools (v0.11.3)	Handscomblie *et al.*[51]	https://kenhanscombe.github.io/ukbtools/
r/data.table (v1.15.4)	Barrett *et al.*[52]	https://r-datatable.com
r/dplyr (v1.1.4)	Wickham *et al.*[53]	https://dplyr.tidyverse.org
r/broom (v1.0.8)	Robinson *et al.*[54]	https://broom.tidymodels.org/
Scripts used for analysis in this study	This study	https://github.com/eilidhfenner/UKBB_RAP_WES)

400 **Table 1 –** Key resources table.

401 ## Method details

402 ### UK Biobank

403 Between 2006 and 2010, the UKBB recruited around 500,000 participants from the UK
404 through NHS registers, with no exclusion criteria apart from reasonable access to an
405 assessment centre. Participants were aged 40-69 at recruitment and 54% were female. All
406 participants gave consent for their data to be used by UKBB projects and agreed to being
407 followed up (Supplementary Materials 1.4). The research presented in this study was
408 conducted using the UKBB resource under Application Number 13310.

409 **Whole exome sequencing data**

410 Whole exome sequencing data for 469,385 UKBB participants were generated using the IDT
411 xGen Exome Research Panel v1.0 exome capture kit and Illumina NovaSeq 6000
412 instruments; S2 flow cells were used for the initial 50k sequencing release, and S4 flow cells
413 used for all following samples. Further details on sequencing protocol can be found in the
414 primary UKBB publication[55].

415 ***Data processing and quality control***

416 WES data was accessed and analysed using the UKBB Research Analysis Platform (RAP).
417 Data was initially accessed as a joint-genotyped variant call set in pVCF format, which was
418 centrally generated by the UKBB with Deep Variant 0.010[56] using CRAMs that were
419 processed using the 'OQFE protocol'[57–60], with reads aligned to GRCh38 reference genome[61].
420 For further details, see [62,63].

421 We performed genotype, sample, and variant QC using Hail (version 0.2.60)[45] running on a
422 JupyterLab instance on the RAP and R (using RStudio v2.2.1) running on a Posit Workbench
423 on the RAP. The original dataset spanned 22,854,479 variants and 469,385 individuals.
424 Multiple steps of variant- and genotype-level QC were undertaken to ensure only high-
425 quality variants remained in the dataset. The number of variants excluded and retained
426 following each QC step are presented in Supplementary Table 15. Genotypes were excluded
427 if they met any of the following criteria: depth ≤ 10x; genotype quality ≤ 30; homozygous
428 genotypes for the reference allele with an allele balance > 0.1; homozygous genotypes for the
429 alternate allele with an allele balance < 0.9; heterozygous genotypes with an allele balance <
430 0.25 or > 0.75. Variant sites were then excluded if they met any of the following criteria:
431 labelled as 'mono-allelic'[64]; > 6 alternative alleles (including indels and SNVs); no
432 alternative alleles after applying genotype QC; within the X or Y chromosome; mean

433 genotype quality across all samples ≤ 40; call rate ≤ 0.9; or overlapped a low-complexity
434 region. In total, 19,724,617 variants remained following variant QC.

435 Sample level QC was undertaken to ensure only samples with high-quality sequencing data
436 remained in the dataset. The number of samples excluded and retained following each QC
437 step are presented in Supplementary Table 16. Participants were excluded if they met any of
438 the following criteria: sequencing call rate < 0.8 (n = 234, Supplementary Figure 5);
439 discordant self-reported sex, imputed sex, and y chromosome depth (n = 210, Supplementary
440 Figure 6, see Supplementary Materials 1.5 for detail); diagnoses of schizophrenia, autism
441 spectrum disorder, or intellectual disability from primary care data, hospital inpatient data,
442 death register records, or self-report (n = 1,526); or insufficient data for inferring ancestries
443 (lacking or low quality array data, n = 1,293). No sample was excluded for low mean
444 sequencing depth or mean genotype quality, most likely because this dataset had already
445 received central QC prior to public release. To identify related individuals, we used estimates
446 of pair-wise kinship co-efficients from array data. The '*ukb_gen_samples_to_remove'*
447 command from the R package ukbtools[51] was used to remove 69,274 samples ensuring that
448 no pairs of retained participants were third degree relations or closer, defined as a kinship co-
449 efficient > 0.0442[65,66]. In total, 72,537 individuals failed sample QC, retaining 396,848
450 individuals for analysis.

451 Analyses for inferring ancestry are based on the procedure described in[67] and updated in[68],
452 and were conducted using UKBB array data. A description of this process is provided in
453 detail in Supplementary Materials 1.1. In short, array data was used alongside
454 biogeographical categories based on a standardised system[69] and a 1KGP Phase 3 reference[30]
455 to infer Ancestry Informative Markers. PC-air was used to compute principal components in

456 the 1KGP reference population, and project UKBB samples into the reference PC co-
457 ordinates. The Tracy-Widom test[70] selected eigenvectors for ancestry inference and a model
458 based on Fisher's Linear Discriminant Analysis[71] was trained on known ancestries of the
459 reference samples, and then applied to the input dataset to predict genetic ancestry
460 probabilities. Genetic ancestry labels were then assigned based on these probabilities. We
461 note that these labels merely reflect genetic similarity to the 1KGP reference panel[30] and do
462 not represent discrete or biologically distinct categories.

463 ***Variant annotation***

464 RCVs, comprising single-nucleotide variants and insertions and deletions < 50 base-pairs in
465 length, were annotated in Hail using Ensembl's VEP[49]. PTVs were defined as splice acceptor,
466 splice donor, stop-gain or frameshift variants that were annotated as high confidence for
467 causing loss of protein function by LoFTEE[31,32]. Deleterious missense variants were defined
468 as missense variants with a REVEL[33] score > 0.75. This REVEL score threshold was chosen
469 based on specificity for predicting deleterious variants in the Human Gene Mutation
470 Database[33]. We also examined rare synonymous variants as a negative control.

471 ***Schizophrenia-associated gene sets***

472 All gene sets are described in detail in Supplementary Table 5. Genes under selective
473 constraint for PTVs, known as LoFi genes, are enriched for damaging RCVs, rare CNVs, and
474 common alleles in schizophrenia[13–15]. We therefore analysed RCVs in 3,162 autosomal LoFi
475 genes (defined as genes with a GnomAD pLI score[34] ≥ 0.9) and in the remaining LoF-tolerant
476 genes (those with a GnomAD pLI score < 0.9). Many schizophrenia-associated gene sets are
477 enriched for genes expressed in the brain. We therefore investigated RCVs in brain expressed
478 genes, defined as genes with an average of > 5 fragments per kilobase of exon model per
479 million mapped reads in the brain in an RNA sequencing study[72].

480 To provide robust evidence that the biology of schizophrenia overlaps with that for cognitive
481 function, we also tested the following sets of protein-coding, autosomal genes implicated in
482 schizophrenia in the largest GWAS[16], CNV[17] and RCV[19] studies of the disorder to date.

483 **RCV enriched genes:** Genes enriched for RCVs in schizophrenia were taken from the
484 SCHEMA study[19]. We analysed 29 autosomal genes enriched for RCVs in schizophrenia at a
485 FDR of < 5%.

486 **Common allele loci:** Genes implicated in schizophrenia by common alleles were taken from
487 the largest schizophrenia GWAS[16]. This study identified 282 autosomal loci associated with
488 schizophrenia and then prioritised credible causal protein-coding genes for some of these loci
489 using fine-mapping and SMR supplemented by chromatin conformation analysis. We
490 analysed three schizophrenia common allele loci gene sets: **1)** all 1,715 genes that overlapped
491 the 282 implicated loci; **2)** 186 genes closest to the index SNP for each associated locus (loci
492 where the nearest gene to the index SNP was non-coding were not included in this analysis);
493 **3**) 101 credible causal protein-coding genes that were prioritised in the original paper[16].

494 **Schizophrenia CNV loci:** A set of 63 CNVs for which there is at least some evidence for
495 association with developmental disorders have been shown to be collectively enriched in
496 people with schizophrenia[17]. We focussed our CNV analysis on 886 genes in regions defined
497 by these 63 CNVs, that we refer to as the schizophrenia-enriched CNV set. 13 of these 63
498 CNVs have individually been associated with schizophrenia with robust statistical
499 significance[17,18], which we refer to as the schizophrenia-associated CNV set (n = 178 genes).
500 To refine which genes within the schizophrenia-enriched CNV set may be contributing to *g*,
501 additional exploratory analyses were performed by testing RCVs only in the schizophrenia-
502 associated CNV loci, and also by testing LoFi and LoF-tolerant genes in the schizophrenia-

503 enriched and schizophrenia-associated CNV sets separately (see Supplementary Table 5 for
504 further details).

505 **Array data**

506 UKBB participants were genotyped using the Affymetrix Axiom UKBB array (~450,000
507 individuals) and the UK BiLEVE array (~50,000 individuals). Schizophrenia PRS were
508 derived via a clumping and thresholding approach in PRSice-2[48] using de-duplicated
509 summary statistics from the largest GWAS of schizophrenia to date[16], as previously
510 described[73,74]. Schizophrenia-enriched CNVs were called as previously described[21].

511 **Phenotypic data**

512 Phenotypic data were collected from UKBB participants at multiple timepoints, in person and
513 online. All participants attended an initial assessment centre where baseline data were
514 collected by: touchscreen questionnaires, including cognitive function measures which took
515 around 5 minutes; a face-to-face interview; and blood sample collection. Participants were
516 later invited to attend additional visits and to complete online questionnaires, including online
517 cognitive test batteries. Where cognitive tests were completed at multiple timepoints, we
518 selected the instance with the greatest sample size for use in our study. Supplementary Table
519 2 provides an overview of the cognitive tests examined in this study and the number of
520 participants who completed them. For all tests, scores were converted to a normal distribution
521 if not already normally distributed and standardised through conversion to z-scores. Outlying
522 scores (outside of +\- 4 standard deviations of the mean) were excluded for each cognitive
523 test.

524 ***Generalised cognition (g)***

525 Cognitive assessments were brief and unsupervised. Individual cognitive tests are known to
526 vary in their reliability and stability[36,75], but performance between different cognitive tests is
527 correlated[75,76] (Supplementary Table 3). The latter property enables *g* to be derived from a PC
528 analysis of multiple cognitive tests[36]. We derived *g* as the first PC from a PC analysis of the
529 following: **1)** Numeric memory (online test battery 1), **2)** Reaction time, **3)** Pairs matching, **4)**
530 Trail making test B (online test battery 1). A detailed description of how *g* was derived, and
531 the rationale for the inclusion/exclusion of individual cognitive tests in *g*, are provided in
532 Supplementary Materials 1.2. In total, we had sufficient data to calculate *g* for 76,783
533 participants.

534 Statistical analysis

535 Linear regression was used to test for association between *g*, the dependent variable, and
536 RCV burden in different schizophrenia-associated gene sets and individual genes. We
537 included as covariates burden of synonymous variants (apart from when investigating
538 synonymous variant burden), sequencing batch and assessment centre. Given cognitive
539 ability is non-linearly associated with age, and that this can differ by sex, we also included
540 covariates for sex and standardised age, standardised age^2, sex*standardised age and sex*
541 standardised age^2.

542 Additionally, we included covariates to control for population stratification, including
543 ancestry probabilities (excluding 1KGP-EUR-like probability, as if all ancestry probabilities
544 were included these would be co-linear), and relevant within ancestry PCs 1-10 (e.g. for
545 analysis of the 1KGP-EUR-like population, the first 10 PCs derived from just this population
546 were included as covariates). For the analysis of the participants who were assigned the
547 'Admixed' 1KGP-like genetic ancestry label (see Supplementary Materials 1.1), we covaried

548 for PCs derived in all participants rather than for within ancestry PCs. All reported regression
549 p-values are two-sided. We explored whether associations of RCV burden and *g* were
550 explained by variation in specific cognitive tests by including individual cognitive test scores
551 as covariates in the analyses of LoFi genes.

552 A multivariable linear regression model was used to test whether damaging RCVs,
553 schizophrenia PRS, and schizophrenia-enriched CNVs had independent effects on cognition.
554 Here, we included all covariates used in the analysis of rare coding variation alone, as well as
555 an additional covariate for genotyping array. This analysis was run in 75,111 individuals of
556 1KGP-EUR-like ancestries in whom *g* could be derived and who had high-quality data for all
557 classes of genetic variation investigated.

558 To compare associations of RCV burden and *g* between gene sets, we performed z-tests using
559 the equation $\frac{(\beta_1 - \beta_2)}{\sqrt{(\sigma_1)^2 + (\sigma_2)^2}}$ where: β_1 is the beta and σ_1 is the standard error of association
560 from the RCV burden in gene set 1; and β_2 is the beta and σ_2 is the standard error of
561 association from the RCV burden in gene set 2. Only independent gene sets were compared
562 using z-tests.

References

1. Saha, S., Chant, D., Welham, J. & McGrath, J. A Systematic Review of the Prevalence of Schizophrenia. *PLOS Med.* **2**, e141 (2005).

2. Perälä, J. *et al.* Lifetime prevalence of psychotic and bipolar I disorders in a general population. *Arch. Gen. Psychiatry* **64**, 19–28 (2007).

3. Sørensen, H. J., Mortensen, E. L., Parnas, J. & Mednick, S. A. Premorbid Neurocognitive Functioning in Schizophrenia Spectrum Disorder. *Schizophr. Bull.* **32**, 578–583 (2006).

4. Reichenberg, A. *et al.* Static and dynamic cognitive deficits in childhood preceding adult schizophrenia: a 30-year study. *Am. J. Psychiatry* **167**, 160–169 (2010).

5. Fusar-Poli, P. *et al.* Cognitive Functioning in Prodromal Psychosis: A Meta-analysis. *Arch. Gen. Psychiatry* **69**, 562–571 (2012).

6. Bowie, C. R., Reichenberg, A., Patterson, T. L., Heaton, R. K. & Harvey, P. D. Determinants of Real-World Functional Performance in Schizophrenia Subjects: Correlations With Cognition, Functional Capacity, and Symptoms. *Am. J. Psychiatry* **163**, 418–425 (2006).

7. Green, M. F., Horan, W. P. & Lee, J. Nonsocial and social cognition in schizophrenia: current evidence and future directions. *World Psychiatry* **18**, 146–161 (2019).

8. Fioravanti, M., Carlone, O., Vitale, B., Cinti, M. E. & Clare, L. A Meta-Analysis of Cognitive Deficits in Adults with a Diagnosis of Schizophrenia. *Neuropsychol. Rev.* **15**, 73–95 (2005).

9. Keefe, R. S. E. *et al.* The Brief Assessment of Cognition in Schizophrenia: reliability, sensitivity, and comparison with a standard neurocognitive battery. *Schizophr. Res.* **68**, 283–297 (2004).

10. Pietrzak, R. H. *et al.* A comparison of the CogState Schizophrenia Battery and the Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) Battery in assessing cognitive impairment in chronic schizophrenia. *J. Clin. Exp. Neuropsychol.* **31**, 848–859 (2009).

11. Green, M. F., Kern, R. S., Braff, D. L. & Mintz, J. Neurocognitive Deficits and Functional Outcome in Schizophrenia: Are We Measuring the "Right Stuff"? *Schizophr. Bull.* **26**, 119–136 (2000).

12. Dickinson, D., Iannone, V. N., Wilk, C. M. & Gold, J. M. General and specific cognitive deficits in schizophrenia. *Biol. Psychiatry* **55**, 826–833 (2004).

13. Singh, T. *et al.* The contribution of rare variants to risk of schizophrenia in individuals with and without intellectual disability. *Nat. Genet.* **49**, 1167–1173 (2017).

14. Rees, E. *et al.* Schizophrenia, autism spectrum disorders and developmental disorders share specific disruptive coding mutations. *Nat. Commun.* **12**, 5353 (2021).

15. Pardiñas, A. F. *et al.* Common schizophrenia alleles are enriched in mutation-intolerant genes and in regions under strong background selection. *Nat. Genet.* **50**, 381–389 (2018).

16. Trubetskoy, V. *et al.* Mapping genomic loci implicates genes and synaptic biology in schizophrenia. *Nature* **604**, 502–508 (2022).

17. Rees, E. *et al.* Analysis of Intellectual Disability Copy Number Variants for Association With Schizophrenia. *JAMA Psychiatry* **73**, 963–969 (2016).

18. Marshall, C. R. *et al.* Contribution of copy number variants to schizophrenia from a genome-wide study of 41,321 subjects. *Nat. Genet.* **49**, 27–35 (2017).

19. Singh, T. *et al.* Rare coding variants in ten genes confer substantial risk for schizophrenia. *Nature* 1–9 (2022) doi:10.1038/s41586-022-04556-w.

20. Liu, D. *et al.* Schizophrenia risk conferred by rare protein-truncating variants is conserved across diverse human populations. *Nat. Genet.* **55**, 369–376 (2023).

21. Kendall, K. M. *et al.* Cognitive Performance Among Carriers of Pathogenic Copy Number Variants: Analysis of 152,000 UK Biobank Subjects. *Biol. Psychiatry* **82**, 103–110 (2017).

22. Stefansson, H. *et al.* CNVs conferring risk of autism or schizophrenia affect cognition in controls. *Nature* **505**, 361–366 (2014).

23. Chen, C.-Y. *et al.* The impact of rare protein coding genetic variation on adult cognitive function. *Nat. Genet.* 1–12 (2023) doi:10.1038/s41588-023-01398-8.

24. Kingdom, R., Beaumont, R. N., Wood, A. R., Weedon, M. N. & Wright, C. F. Genetic modifiers of rare variants in monogenic developmental disorder loci. *Nat. Genet.* **56**, 861–868 (2024).

25. Lencz, T. *et al.* Molecular genetic evidence for overlap between general cognitive ability and risk for schizophrenia: a report from the Cognitive Genomics consorTium (COGENT). *Mol. Psychiatry* **19**, 168–174 (2014).

26. Mallet, J., Le Strat, Y., Dubertret, C. & Gorwood, P. Polygenic Risk Scores Shed Light on the Relationship between Schizophrenia and Cognitive Functioning: Review and Meta-Analysis. *J. Clin. Med.* **9**, 341 (2020).

27. Gardner, E. J. *et al.* Reduced reproductive success is associated with selective constraint on human genes. *Nature* **603**, 858–863 (2022).

28. Nuechterlein, K. H. *et al.* Identification of separable cognitive factors in schizophrenia. *Schizophr. Res.* **72**, 29–39 (2004).

29. Schaefer, J., Giangrande, E., Weinberger, D. R. & Dickinson, D. The global cognitive impairment in schizophrenia: Consistent over decades and around the world. *Schizophr. Res.* **150**, 42–50 (2013).

30. Auton, A. *et al.* A global reference for human genetic variation. *Nature* **526**, 68–74 (2015).

31. Karczewski, K. J. *et al.* The mutational constraint spectrum quantified from variation in 141,456 humans. *Nature* **581**, 434–443 (2020).

32. Karczewski, K. konradjk/loftee. (2020).

33. Ioannidis, N. M. *et al.* REVEL: An Ensemble Method for Predicting the Pathogenicity of Rare Missense Variants. *Am. J. Hum. Genet.* **99**, 877–885 (2016).

34. Lek, M. *et al.* Analysis of protein-coding genetic variation in 60,706 humans. *Nature* **536**, 285–291 (2016).

35. McCutcheon, R. A., Keefe, R. S. E. & McGuire, P. K. Cognitive impairment in schizophrenia: aetiology, pathophysiology, and treatment. *Mol. Psychiatry* 1–17 (2023) doi:10.1038/s41380-023-01949-9.

36. Fawns-Ritchie, C. & Deary, I. J. Reliability and validity of the UK Biobank cognitive tests. *PLoS ONE* **15**, (2020).

37. Johnson, W., Nijenhuis, J. te & Bouchard, T. J. Still just 1 g: Consistent results from five test batteries. *Intelligence* **36**, 81–95 (2008).

38. Johnson, W., Bouchard, T. J., Krueger, R. F., McGue, M. & Gottesman, I. I. Just one g: consistent results from three test batteries. *Intelligence* **32**, 95–107 (2004).

39. Kennedy, M. B. Synaptic Signaling in Learning and Memory. *Cold Spring Harb. Perspect. Biol.* **8**, a016824 (2016).

40. MacLeod, A. K. *et al.* Genetic Copy Number Variation and General Cognitive Ability. *PLOS ONE* **7**, e37385 (2012).

41. Smeland, O. B., Frei, O., Dale, A. M. & Andreassen, O. A. The polygenic architecture of schizophrenia — rethinking pathogenesis and nosology. *Nat. Rev. Neurol.* **16**, 366–379 (2020).

42. Rolland, T. *et al.* Phenotypic effects of genetic variants associated with autism. *Nat. Med.* 1–10 (2023) doi:10.1038/s41591-023-02408-2.

43. Fry, A. *et al.* Comparison of Sociodemographic and Health-Related Characteristics of UK Biobank Participants With Those of the General Population. *Am. J. Epidemiol.* **186**, 1026–1034 (2017).

44. Schoeler, T. *et al.* Participation bias in the UK Biobank distorts genetic associations and downstream analyses. *Nat. Hum. Behav.* **7**, 1216–1227 (2023).

45. Hail Team. Hail. https://github.com/hail-is/hail.

46. Chang, C. C. *et al.* Second-generation PLINK: rising to the challenge of larger and richer datasets. *GigaScience* **4**, s13742-015-0047–8 (2015).

47. Euesden, J., Lewis, C. M. & O'Reilly, P. F. PRSice: Polygenic Risk Score software. *Bioinformatics* **31**, 1466–1468 (2015).

48. Choi, S. W. & O'Reilly, P. F. PRSice-2: Polygenic Risk Score software for biobank-scale data. *GigaScience* **8**, giz082 (2019).

49. McLaren, W. *et al.* The Ensembl Variant Effect Predictor. *Genome Biol.* **17**, 122 (2016).

50. Wickham, H. *Ggplot2*. (Springer International Publishing, Cham, 2016). doi:10.1007/978-3-319-24277-4.

51. Hanscombe, K. ukbtools: Manipulate and Explore UK Biobank Data. (2019).

52. Extension of `data.frame`. https://rdatatable.gitlab.io/data.table/.

53. A Grammar of Data Manipulation. https://dplyr.tidyverse.org/.

54. Convert Statistical Objects into Tidy Tibbles. https://broom.tidymodels.org/.

55. Van Hout, C. V. *et al.* Exome sequencing and characterization of 49,960 individuals in the UK Biobank. *Nature* **586**, 749–756 (2020).

56. Poplin, R. *et al.* A universal SNP and small-indel variant caller using deep neural networks. *Nat. Biotechnol.* **36**, 983–987 (2018).

57. Szustakowski, J. D. *et al.* Advancing human genetics research and drug discovery through exome sequencing of the UK Biobank. *Nat. Genet.* **53**, 942–948 (2021).

58. Regier, A. A. *et al.* Functional equivalence of genome sequencing analysis pipelines enables harmonized variant calling across human genetics projects. *Nat. Commun.* **9**, 4038 (2018).

59. Krasheninina, O. *et al.* Open-source mapping and variant calling for large-scale NGS data from original base-quality scores. 2020.12.15.356360 Preprint at https://doi.org/10.1101/2020.12.15.356360 (2020).

60. dnanexus/oqfe. https://hub.docker.com/r/dnanexus/oqfe.

61. GRCh38 - hg38 - Genome - Assembly - NCBI. https://www.ncbi.nlm.nih.gov/assembly/GCF_000001405.26/.

62. UKB Showcase: WES protocol. https://biobank.ndph.ox.ac.uk/showcase/refer.cgi?id=915.

63. UKB Showcase: Exome Sequences. https://biobank.ndph.ox.ac.uk/showcase/label.cgi?id=170.

64. Lin, M. F. *et al.* GLnexus: joint variant calling for large cohort sequencing. *bioRxiv* 343970 (2018) doi:10.1101/343970.

65. Relationship Inference in KING. https://www.kingrelatedness.com/manual.shtml.

66. Manichaikul, A. *et al.* Robust relationship inference in genome-wide association studies. *Bioinformatics* **26**, 2867–2873 (2010).

67. Legge, S. E. *et al.* A genome-wide association study in individuals of African ancestry reveals the importance of the Duffy-null genotype in the assessment of clozapine-related neutropenia. *Mol. Psychiatry* **24**, 328–337 (2019).

68. Smart, S. E. *et al.* SLC39A8.p.(Ala391Thr) is associated with poorer cognitive ability: a cross-sectional study of schizophrenia and the general UK population. 2024.09.18.24313865 Preprint at https://doi.org/10.1101/2024.09.18.24313865 (2024).

69. Huddart, R. *et al.* Standardized Biogeographic Grouping System for Annotating Populations in Pharmacogenetic Research. *Clin. Pharmacol. Ther.* **105**, 1256–1262 (2019).

70. Patterson, N., Price, A. L. & Reich, D. Population Structure and Eigenanalysis. *PLOS Genet.* **2**, e190 (2006).

71. Yang, N. *et al.* Examination of ancestry and ethnic affiliation using highly informative diallelic DNA markers: application to diverse and admixed populations and implications for clinical epidemiology and forensic medicine. *Hum. Genet.* **118**, 382–392 (2005).

72. Fagerberg, L. *et al.* Analysis of the human tissue-specific expression by genome-wide integration of transcriptomics and antibody-based proteomics. *Mol. Cell. Proteomics MCP* **13**, 397–406 (2014).

73. Legge, S. E. *et al.* Association of Genetic Liability to Psychotic Experiences With Neuropsychotic Disorders and Traits. *JAMA Psychiatry* **76**, 1256–1265 (2019).

74. Legge, S. E. *et al.* Genetic and Phenotypic Features of Schizophrenia in the UK Biobank. *JAMA Psychiatry* **81**, 681–690 (2024).

75. Lyall, D. M. *et al.* Cognitive Test Scores in UK Biobank: Data Reduction in 480,416 Participants and Longitudinal Stability in 20,346 Participants. *PLoS ONE* **11**, e0154222 (2016).

76. Spearman, C. *'General Intelligence' Objectively Determined and Measured*. 73 (Appleton-Century-Crofts, East Norwalk, CT, US, 1961). doi:10.1037/11491-006.

Acknowledgments

We thank George Kirov for contributions to CNV calling, Antonio Pardiñas for developing the pipeline from which we worked to infer genetic ancestries, and Sophie Legge for performing quality control of the array data and deriving schizophrenia polygenic risk scores.

This work was supported by a UKRI MRC Programme Grant (MR/Y004094/1) to JTRW, ER, PH, MCOD and MJO, a Wellcome Trust Integrative Neuroscience PhD Studentship to EF (108891/B/15/Z /WT), a UKRI Future Leaders Fellowship Grant to ER (MR/T018712/1 and MR/Y033922/1).

This research has been conducted using the UK Biobank Resource under Application Number 13310. This work uses data provided by patients and collected by the NHS as part of their care and support: Copyright © (2023), NHS England; Re-used with the permission of the NHS England and UK Biobank; All rights reserved.

This research used data assets made available by National Safe Haven as part of the Data and Connectivity National Core Study, led by Health Data Research UK in partnership with the Office for National Statistics and funded by UK Research and Innovation (research which commenced between 1st October 2020 – 31st March 2021 (MC_PC_20029); 1st April 2021 - 30th September 2022 (MC_PC_20058).

Author contributions

E.F., E.R., and J.T.R.W. conceived and designed the research. E.F. and E.R. analysed the data. E.F., E.R., J.T.R.W., P.H., M.C.O.D. and M.J.O. contributed to the interpretation of the

results. E.F., E.R., and J.T.R.W. wrote the manuscript, which was read, edited and approved by all authors.

Declaration of interests

ER, JTRW, MCO and MJO reported receiving grants from Akrivia Health outside the submitted work. JTRW, MJO and MCO reported receiving grants from Takeda Pharmaceutical Company Ltd outside the submitted work. Takeda and Akrivia played no part in the conception, design, implementation, or interpretation of this study.

Resource Availability

Lead contact

Requests for further information and resources should be directed to and will be fulfilled by the lead contact, Dr. Elliott Rees (ReesEG@cardiff.ac.uk).

Data availability

This study used data from the UK Biobank, which is available for health-related research upon registration and application through the UK Biobank Access Management System (https://www.ukbiobank.ac.uk/enable-your-research/register). The code required to reproduce our analyses is publicly available (https://github.com/eilidhfenner/UKBB_RAP_WES).

Supplemental information

Supplementary_Materials.docx : Supplementary Materials and Supplementary Figures 1-6.

Supplementary_Tables.xlsx : Supplementary Tables 1-16.